Explore our brands

Our brands bring together the industry's most influential leaders and scientific experts, inspiring thought-provoking and insightful content that offers a unique perspective on R&D trends and challenges.
Contact

Resources

The latest in from biologics discovery and development through to production and supply chain management.

Top R&D Stories of 2023

Through captivating articles, insight pieces, and spotlight interviews, we delve into the remarkable innovations, breakthroughs, and scientific marvels that have defined the landscape of research over the past year.
Read Now
Vaccines

The Race for an RSV Vaccine Approval

Things are heating up in the race to pinch the first FDA approval of an RSV vaccine, as Moderna joins Pfizer and GSK in the running.
Read More
Vaccines

Dual-Action Malaria Vaccine Takes the Punch out of the Parasite

A new vaccine duo developed by scientists at George Washington University stops malaria infection and transmission, the double attack needed to eradicate the disease.
Read More
Vaccines

Nexelis’s Collaborative Development for Optimal Clinical Assay

November’s webinar, Adaptive Laboratory Environment: Collaboration Across our Development Teams Produces Optimal Clinical Assay, discusses Nexelis’s process in recombinant protein production, optimisation, and characterisation.
Read More
Vaccines

Overcoming Vaccine Manufacturing Challenges

Experts from King’s College London, Janssen, and Merck Sharp & Dohme congregate to talk the future of optimised vaccine manufacturing.
Read More
Vaccines

Vaccines After COVID: How the Pandemic Has Changed the Vaccination Market

During the pandemic, a layperson couldn't avoid learning about vaccinations. But as the world returns to “normal”, how does this new-found focus on vaccines manifest for regulators, producers, prescribers, and the public? 
Read More
Vaccines

Vaccines Europe: Presentations You Won’t Want to Miss

Find out about some of Oxford Global’s most highly anticipated presentations happening at our upcoming Vaccines Congress.
Read More
Vaccines

Universal Vaccines & Vaccine Therapeutics

Mark Doherty, Senior Medical Manager at GSK, leads a Discussion Group on leveraging the mechanisms of action in therapeutic vaccine development.
Read More
Vaccines

3-Dose Hepatitis B Vaccine Offers Full Protection for People with HIV

Phase III clinical trials from the University of Cincinnati have shown seroprotection in 100% of HIV-positive participants after a 3-dose regimen of the HEPLISAV-B vaccine.
Read More
Vaccines

Why We Develop Autoimmunity: Hyperstimulation of Genetically Prone Subjects

Professor Yehuda Shoenfeld explains his findings in establishing links between genetic predisposition and hyperstimulation of the immune system and how this may help us better understand the development of autoimmunity.
Read More
Vaccines

Advanced Vaccine Platforms & Technologies

Wieslaw Swietnicki, Head of Biosynthesis and Bioengineering Group at the Institute of Industrial Organic Chemistry, leads a discussion on the current outlook for advanced vaccine platforms, technologies, and development.
Read More
Vaccines

Pfizer’s Pneumococcal Vaccine Shows Great Promise in European Study

Pfizer’s new PCV candidate is set to become the most effective protector against pneumococcal infections for infants.
Read More
Vaccines

Using Humanised Mice to Evaluate Vaccine Efficacy

Kymab Ltd presents the utility of mice models for studying human immune response to complex vaccines.
Read More

Subscribe to Our Newsletter

Sign up for our monthly newsletter to
keep up with all things biologics